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Vascular development begins when mesodermal
cells differentiate into endothelial cells, which then
form primitive vessels. It has been hypothesized
that endothelial-specific gene expression may be
regulated combinatorially, but the transcriptional
mechanisms governing specificity in vascular gene
expression remain incompletely understood. Here,
we identify a 44 bp transcriptional enhancer that is
sufficient to direct expression specifically and exclu-
sively to the developing vascular endothelium. This
enhancer is regulated by a composite cis-acting ele-
ment, the FOX:ETS motif, which is bound and syner-
gistically activated by Forkhead and Ets transcription
factors. We demonstrate that coexpression of the
Forkhead protein FoxC2 and the Ets protein Etv2 in-
duces ectopic expression of vascular genes in Xeno-
pus embryos, and that combinatorial knockdown of
the orthologous genes in zebrafish embryos disrupts
vasculardevelopment. Finally,weshow thatFOX:ETS
motifs are present in many known endothelial-spe-
cific enhancers and that this motif is an efficient pre-
dictor of endothelial enhancers in the humangenome.
INTRODUCTION
The establishment of the vascular system begins prior to the
beating of the heart and initially forms through a process referred
to as vasculogenesis. Mesodermal cells differentiate into endo-
thelial cell precursors and form primitive vessels, which are
then rapidly remodeled through endothelial sprouting, branch-
ing, and intussusception from existing blood vessels (Flamme
et al., 1997; Patan, 2004). This highly organized developmental
program requires the correct spatial and temporal expression
of a large number of genes; yet despite the importance of the
vasculature in development and disease, the transcriptionalmechanisms governing gene expression in these processes
remain incompletely understood.
The Ets family of winged helix proteins plays a clear role in the
transcriptional control of genes involved in vascular develop-
ment (Dejana et al., 2007; Sato, 2001). All Ets factors share
a highly conserved DNA-binding domain and bind to the core
DNA sequence GGA(A/T), and nearly every endothelial cell en-
hancer or promoter characterized to date contains multiple es-
sential Ets-binding sites (Dejana et al., 2007; Sato, 2001). Of
the nearly 30 different members of the mammalian Ets family,
at least 19 are expressed in endothelial cells, and several have
been shown to play essential roles in vascular development (Hol-
lenhorst et al., 2004). However, no Ets factor is unique to the vas-
culature, and Ets-binding sites are not specific to endothelial-
expressed genes (Hollenhorst et al., 2004; Maroulakou and
Bowe, 2000). Thus, it is unclear exactly how Ets factors contrib-
ute to the specificity of endothelial gene regulation. It has been
hypothesized that Ets proteins may achieve tissue-specific acti-
vation through binding to lower affinity sites in cooperation with
other proteins (Hollenhorst et al., 2007), but Ets partners in endo-
thelial cells have yet to be identified.
Members of the Forkhead (Fox) transcription factor family
also play important roles in vascular endothelial development.
Forkhead transcription factors are helix-turn-helix proteins
that typically bind asymmetric cis-acting elements of 15–17 bp,
containing the core Fox protein consensus of RYMAAYA
(Carlsson and Mahlapuu, 2002). FoxC1 and FoxC2 are ex-
pressed in the developing vasculature, although not exclusively,
and Foxc1/Foxc2 compound null embryos die during embryonic
development with profound vascular defects (Hosaka et al.,
2004; Seo et al., 2006). However, the mechanisms by which
Forkhead transcription factors control endothelial gene expres-
sion are not clear. It has been hypothesized that gene expres-
sion in the endothelium may be regulated via the combined
action of multiple transcription factors, but direct evidence for
such a putative combinatorial control mechanism has been
lacking.
In the present study, we identified a 44 bp transcriptional en-
hancer that is sufficient to direct expression specifically andCell 135, 1053–1064, December 12, 2008 ª2008 Elsevier Inc. 1053
Figure 1. Identification of a 44 bp Mef2c Endothelial-Specific Enhancer
(A) A schematic representation of the mouse Mef2c locus is shown on the top line with exons depicted as vertical lines. The red boxes denote the sizes and
positions of the F7 and F10 fragments. F10 contains three evolutionarily conserved regions, denoted CR1–3. The lower portion of (A) depicts the deletion con-
structs ofMef2c F10. CR3 contains a neural crest-specific enhancer. CR2 contains an endothelial-specific enhancer, which encompasses a 44 bp deeply con-
served region that is sufficient for endothelial enhancer activity in vivo. Endothelial and neural crest activity of each of the deletion constructs is denoted at the right
as a + or . The total number of transgenic embryos and the number that directed b-galactosidase expression to either the neural crest or endothelium are
denoted at the far right of (A).
(B–G) Representative X-gal stained transgenic embryos for each of the Mef2c F10 transgene deletion constructs depicted in (A).
(H–M) Expression of the Mef2c F10-44-lacZ construct is specific to endothelial cells from blood island (bl) stage at E7.5 (H) throughout early endothelial devel-
opment at E8.0 (I) and E8.5 (J and K). Transverse sections through an X-gal stained E9.5 transgenic embryo (L and M) demonstrate that transgene expression is
restricted to endothelial cells throughout the vasculature, including the endocardium (end). al, allantois; BAA, branchial arch artery; CV, cardinal vein; DA, dorsal
aorta; DRG, dorsal root ganglia; ec, ectoplacental cone; hrt, heart; LV, left ventricle; NC, neural crest; NT, neural tube; RV, right ventricle; SV, sinus venosus; YS,
yolk sac.exclusively to the developing vascular endothelium. This en-
hancer is regulated by a composite cis-acting element, the FOX:
ETS motif, which is bound and synergistically activated by Fork-
head and Ets transcription factors. We demonstrate that coex-
pression of FoxC2 and the Ets protein Etv2 (Etsrp71, ER71) is
sufficient to induce ectopic expression of vascular genes in
Xenopus embryos, and that combinatorial knockdown of the or-
thologous genes in zebrafish embryos disrupts vascular devel-
opment. Finally, we show that FOX:ETS motifs are present in
many known endothelial-specific enhancers and that this motif
is an efficient predictor of endothelial enhancers in the human
genome. Thus, these studies provide insight into the specificity
requirements for endothelial gene expression by the combinato-
rial activities of two widely expressed transcription factors on
a single composite cis-acting element.1054 Cell 135, 1053–1064, December 12, 2008 ª2008 Elsevier Inc.RESULTS
Identification of a 44 bp Enhancer Sufficient
to Direct Expression Exclusively to Endothelial
Cells in the Developing Embryo
The MEF2C transcription factor is expressed in endothelial cells
soon after their initial specification and is essential for vascular
development in mice (Lin et al., 1998; Figure S1 available online).
Based on evolutionary conservation, we identified a 5.6 kb re-
gion of the Mef2c locus (F10) that contained two separate
enhancers that each direct expression to a single lineage in the
developing mouse embryo (Figure 1A). The activity of one en-
hancer was specific to the developing vascular endothelium
(F10E), and the activity of the other was restricted to the neural
crest and its derivatives (F10N) at E9.5 (Figures 1A–1D). Mef2c
F10E is a distinct regulatory element from a previously identified
enhancer, termed Mef2c F7 (Figure 1A), which also directs vas-
cular expression in vivo, although not as early in endothelial de-
velopment as F10E (De Val et al., 2004). Mef2c F10E contains
a highly conserved 44 bp region that shares 86% sequence ho-
mology with zebrafish (Danio rerio) (Figure 2A). Deletion of this
deeply conserved 44 bp fragment in the context of F10E or in
the context of the larger 5.6 kb F10 construct resulted in the
complete loss of endothelial expression (Figures 1F and 1G). Re-
markably, the 44 bp deeply conserved region of F10 (F10-44)
was sufficient to direct endothelial cell-specific expression
from the blood island stage at E7.5 through angiogenesis and re-
modeling at E9.5 (Figures 1E and 1H–1M). These results indicate
that this minimal 44 bp region contains all the cis-regulatory in-
formation necessary for endothelial-specific gene activation
and expression and thus presented the opportunity to identify
a minimal set of transcription factors sufficient to regulate endo-
thelial-specific gene expression.
TheMef2c F10E Enhancer Is Bound and Synergistically
Activated by Fox and Ets Transcription Factors
through a Novel cis-Acting Motif
To locate transcription factor-binding sites within F10-44, we
used DNaseI footprinting to identify a region at the 30 end of
F10-44 bound by an activity present in endothelial cell extracts
but not in extracts from myoblasts (Figure S2). Within this
region, we identified a consensus ETS site, containing the core
GGA(A/T) motif, referred to as ETS-A (Figure 2A). While multiple
Ets factors bound to ETS-A in electrophoreticmobility shift assay
(EMSA) (Figure 2B and data not shown), Etv2 displayed the
strongest binding (Figure 2B). We also identified a second ETS
site within Mef2c F10-44 (ETS-B), which was also bound by
several distinct Ets proteins in EMSA, including Etv2 (data
not shown). A third potential core ETS-binding site (TTCC) in
F10-44, located between ETS-A and ETS-B, was not bound in
EMSA by Etv2 or the Ets-1 DNA-binding domain (DBD) under
conditions in which the control ETS site, ETS-A, and ETS-B
were each robustly bound (data not shown).
In addition to the ETS sites, the footprinting studies showed an
additional endothelial-specific activity immediately adjacent to
the ETS-A site (Figure S2). This adjacent sequence had weak
similarity to the core Forkhead binding site RYMAAYA (Carlsson
and Mahlapuu, 2002), so we performed EMSA to determine
whether the footprinted region was bound by different subfam-
ilies of Forkhead transcription factors (Figure 2C). Indeed,
FoxC1 and FoxC2 bound robustly to this noncanonical Forkhead
site (FOX-NC; Figure 2C, lanes 10–13), and this binding was
disrupted by a 3 bp mutation within FOX-NC (Figure 2C,
lanes 14–17), suggesting that these Forkhead proteins bind to
a broader consensus site than previously thought. FoxO1 also
bound to the FOX-NC site, albeit less robustly than FoxC1 or
FoxC2 (Figure 2C, lanes 8–9). FoxA2, FoxF1, and FoxH1 did
not display any detectable binding to FOX-NC in EMSA
(Figure 2C, lanes 2–7), although each protein was efficiently syn-
thesized in vitro and each bound to its own canonical site in the
same assay (Figure S3). In addition, we performed chromatin
immunoprecipitation (ChIP) analyses on primary mouse embryo
fibroblasts transfected with an epitope-tagged FoxC2 construct,which demonstrated that FoxC2 could bind to the endogenous
F10-44 enhancer in vivo (Figure 2D). No binding of FoxC2
protein was detected in ChIP analyses of the skeletal muscle-
specificmyogenin promoter, which served as a nonspecific con-
trol (Figure 2D).
Next, we tested the ability of FoxC and Ets transcription fac-
tors to activate the F10E enhancer (Figure 2E). Alone, FoxC2
and Etv2 activated the Mef2c F10E enhancer 3-fold and 7-fold,
respectively (Figure 2E, lanes 2 and 3). Strikingly, the combina-
tion of the two factors resulted in more than 40-fold synergistic
activation (Figure 2E, lane 4). A 3 bp mutation that disrupted
the binding of Etv2 and FoxC2 to the FOX:ETS motif in EMSA re-
sulted in nearly complete disruption of transactivation (Figure 2E,
lane 8), demonstrating the specificity of this activation.
The strong synergistic activation of theMef2c F10E enhancer
by FoxC2 and Etv2, combined with the immediate juxtaposition
of the two binding sites, suggested that the two factors might be
simultaneously binding to the FOX:ETS motif to activate tran-
scription. To determine if FoxC2 and Etv2 bound to the FOX:ETS
motif simultaneously, EMSA were performed in which increasing
amounts of FoxC2 were added to a constant amount of Etv2 and
theMef2c F10-44 FOX:ETS motif (Figure 2F). As expected, Etv2
bound the FOX:ETS motif in the absence of FoxC2 (Figure 2F,
lane 5). Addition of FoxC2 to the binding reactions resulted in
the presence of probe bound solely by FoxC2 and in the forma-
tion of a complex of Etv2, FoxC2, and the FOX:ETS motif (Fig-
ure 2F, lanes 6–8). The slower mobility band suggests that
FoxC2 and Etv2 form a ternary complex that requires both pro-
teins and DNA. The ternary complex increased in abundance
with increasing quantities of FoxC2 relative to Etv2 even in the
presence of large amounts of excess free probe (Figure 2F, lanes
6–8). These results support the notion that FoxC2 and Etv2 co-
occupy the FOX:ETS motif simultaneously and suggest that
the two proteins may function together as part of a ternary com-
plex to synergistically activate transcription.
To define the role of the FOX:ETS motif in vivo, we introduced
a 3 bp mutation into this element in the context of the full-length
5.6 kb F10 fragment and used this mutant construct to generate
transgenic mouse embryos (Figure 2G). Mef2c F10 contains
both the F10E endothelial and F10N neural crest enhancers
(Figure 1A). Disruption of the FOX:ETS motif resulted in a com-
plete loss of endothelial activity, while neural crest activity was
unperturbed (Figure 2G, F10 mutFEM). In addition, mutation of
the second ETS site within F10-44 also resulted in a disruption
of endothelial activity of the full-length F10 enhancer, while
leaving neural crest activity undisturbed (Figure 2G, F10
mutETS-B).
Expression of FoxC2 and Etv2 in Xenopus Embryos
Induces Ectopic Vascular Gene Expression
To test whether FoxC2 and Etv2 were sufficient to induce endo-
thelial-specific gene activation more generally, we coinjected
mRNAs for FoxC2 and Etv2 into a single cell at the vegetal
pole of Xenopus embryos at the 4-cell stage (Figure 3). Remark-
ably, the two factors potently induced endothelial-specific gene
expression in a normally avascular region of the endoderm in the
tail region of the frog tadpole. In embryos injected with FoxC2
and Etv2, multiple regions of flk1mRNA expression were readilyCell 135, 1053–1064, December 12, 2008 ª2008 Elsevier Inc. 1055
Figure 2. Identification of a Novel FOX:ETS Motif Simultaneously Bound and Synergistically Activated by FoxC2 and Etv2
(A) Alignment of the mouse and zebrafishMef2c F10-44 sequences. Red boxes denote core ETS-binding sites, and the blue box denotes a nonconsensus Fork-
head-binding element (FOX-NC). The novel, composite FOX:ETS motif is indicated above. Consensus Forkhead- and Ets-binding sites (Hollenhorst et al., 2007;
Carlsson and Mahlapuu, 2002) are denoted, as is the mutant FOX:ETS sequence used in these studies.
(B) Radiolabeled oligonucleotide probes encompassing the F10-44 ETS-A site were used in EMSAwith recombinant Ets proteins. The Ets1 DNA-binding domain
(DBD) and Etv2 efficiently bound to the site (lanes 2 and 11) and were competed by excess unlabeled self probe (wt, lanes 3 and 12) but not by mutant self-probe
(mu, lanes 4 and 13). Erg and Elf-1 displayed little or no detectable binding to ETS-A in this assay.
(C) A radiolabeled oligonucleotide probe encompassing theMef2c F10-44 FOX-NC site was used in EMSA with recombinant Forkhead proteins. FoxA2, FoxF1,
and FoxH1 showed weak or no binding to FOX-NC. FoxO1 (lanes 8 and 9) showed weak binding to FOX-NC. FoxC1 (lanes 10 and 11) and FoxC2 (lanes 12, 13;
also lanes 14–17) exhibited robust binding. Addition of excess, unlabeled self-probe, indicated by a + sign, inhibited binding of FoxO1, FoxC1, and FoxC2 to the
FOX-NC site (lanes 9, 11, and 13). Additionally, inclusion of a mutant version of FOX-NC (lane 17, mu) did not inhibit binding of FoxC2 to FOX-NC at the same
concentration that the wild-type self-probe completely abolished binding (lane 16, wt).1056 Cell 135, 1053–1064, December 12, 2008 ª2008 Elsevier Inc.
observed in nearly all embryos examined (Figure 3B). By con-
trast, injection of control mRNAs resulted in no induction of flk1
expression (Figure 3A). Quantification of flk1 expression in the
abdominal region of injected frog embryos by real-time PCR
showed that FoxC2 and Etv2 were each able to weakly induce
the expression of flk1, while the combined expression of the
two factors resulted in a synergistic level of activation of flk1 ex-
pression more than 25-fold higher than in control injected em-
bryos (Figure 3C). Coexpression of FoxC2 and Etv2 in Xenopus
embryos also resulted in strong synergistic and ectopic activa-
tion of Pecam expression (Figure 3D). These results demonstrate
that FoxC2 and Etv2 are sufficient to induce the expression of
endogenous endothelial genes in vivo.
The Combined Functions of FoxC and Ets Proteins Are
Required for Vascular Development in Zebrafish
Consistent with the deep conservation of F10-44, the mouse
Mef2c F10E enhancer directed the expression of a GFP trans-
gene in a vascular-specific manner in zebrafish at 48 hr post-
fertilization (hpf) (Figures 4A and 4B). Indeed, the expression
directed byMef2c F10E was nearly identical to the GFP expres-
sion observed in the Tg(flk1:GFP)s843 line, which is specific to en-
dothelial cells at 48 hpf (Jin et al., 2005) (Figures 4C and 4D).
These observations indicate that the transcriptional pathways
governing endothelial cell gene expression in zebrafish utilize
the same cis-elements as in the mouse, supporting the notion
that the same transcriptional requirements are involved in endo-
thelial enhancer regulation in the two organisms.
The orthologs of mammalian Ets factors are essential for vas-
cular development in zebrafish (Pham et al., 2007; Sumanas and
Lin, 2006), but the involvement of FoxC proteins in this process
has not been described in zebrafish. We first examined the
expression pattern of the zebrafish FoxC orthologs foxc1a and
foxc1b (Topczewska et al., 2001). Both genes were expressed
in the vasculature during the early stages of vascular develop-
ment, including in the coalescing endothelial cells of the axial
vessels at 24 hpf (Figures 4E–4H). We next tested the require-ment of foxc genes in zebrafish by morpholino knockdown
(Figures 4I–4L). Control morpholino-injected embryos displayed
normal vascular development, which could be observed by the
expression of Tg(flk1:GFP)s843 and normal accumulation of
blood in the heart, as evidenced by the expression of Tg(ga-
ta1:DsRed)sd2 (Figure 4I). Knockdown of foxc1a resulted in a
decrease in intersomitic vessel sprouting, although the trunk
vasculature still formed (Figure 4J). Knockdown of foxc1b using
a similar concentration of morpholino had a less profound effect
on vascular development at 24 hpf (Figure 4K). Importantly,
combinatorial knockdown of both proteins resulted in a more
severe vascular phenotype. No intersomitic vessel sprouts
were detected at 24 hpf, and the formation of the axial vessels
was severely diminished (Figure 4L). These data suggest that
FoxC proteins are required for vascular development in
zebrafish.
In previous studies, it was noted that high-concentration mor-
pholino knockdown of single ets genes had some effect on vas-
cular development in the fish,most notably with etsrp (ets1b), the
zebrafish ortholog of Etv2 (Pham et al., 2007; Sumanas et al.,
2008; Sumanas and Lin, 2006). However, injection of a low
dose of etsrpmorpholino (0.5 ng) resulted in no discernable phe-
notype at 24 hpf (Figure 4O). Similarly, injection of a lower dose of
foxc1a morpholino (4 ng) than that used in the experiments
shown in Figure 4J resulted in little or no vascular phenotype at
24 hpf (Figure 4N). Remarkably, coinjection of the same sub-
phenotypic doses of etsrp and foxc1a morpholinos resulted in
a nearly complete ablation of vascular development, as indi-
cated by dramatically reduced Tg(flk1:GFP)s843 expression
(Figure 4P). Since the flk1-gfp construct used to visualize the
vasculature may itself be a direct target of FoxC1a and Etsrp,
we also used the Tg(gata1:DsRed)sd2 line to visualize blood cells.
Consistent with failed circulation due to severely disrupted vas-
cular development, we observed massive pooling of blood in the
tail in the double morpholino-injected embryos (Figure 4P).
These results provide additional strong support for an essential
role for FoxC and Ets factors in vascular development.(D) Chromatin immunoprecipitation from mouse embryo fibroblasts transfected with pCDNA3.1-FoxC2-Flag (C2) or parental pCNA3.1 expression vector (ctrl).
Sheared, crosslinked chromatin fragments were immunoprecipitated with anti-FLAG antibody and the region of the endogenous Mef2c locus, surrounding
F10-44, was amplified by PCR (upper panel). As a control, the region surrounding the myogenin skeletal muscle promoter was amplified by PCR (lower panel).
TheMef2c F10-44 region was specifically amplified in pDNA3.1-FoxC2-FLAG transfected cells (lane 5), similar to the amplification in control samples that were
directly amplified without prior immunoprecipitation (input, lanes 1 and 3). No amplification was detected in control transfected (lane 2) or nonspecific IgG im-
munoprecipitated samples (lane 4). The myogenin promoter was not amplified in pCDNA3.1-FoxC2-FLAG transfected cells under conditions in which the
Mef2c F10-44 region was amplified (lower panel, lane 5).
(E) FoxC2 and Etv2 synergistically trans-activate theMef2c F10E enhancer. FoxC2 and Etv2 each weakly activated the reporter (lanes 2 and 3) compared to pa-
rental expression plasmid control transfections (lane 1). Cotransfection of the reporter with expression plasmids for FoxC2 and Etv2 together resulted in potent
synergistic activation (lane 4). Mutation of the FOX:ETS motif (mutFEM) ablated activation by FoxC2 and Etv2 (lanes 5–8). Data are presented as the mean fold
activation for four independent sets of transfections and analyses. Error bars indicate the standard error of the mean (SEM).
(F) FoxC2 and Etv2 simultaneously bind the FOX:ETS motif. A radiolabeled oligonucleotide probe (Mef2c-F10 FOX:ETS) encompassing only the F10E FOX:ETS
motif was used in EMSA with recombinant FoxC2 and Etv2. The labeled probe included the FOX:ETS motif plus short adjacent sequences and did not include
additional potential ETS-binding sites. Increasing amounts of FoxC2 in the absence of Etv2 resulted in the formation of an increasing amount of FoxC2-DNA
complex (lanes 2–4). Addition of Etv2 alone resulted in the formation of an Etv2-DNA complex (lane 5). Addition of increasing amounts of FoxC2 in the presence
of a constant amount of Etv2 resulted in formation of each individual protein-DNA complex as well as a slower mobility band, suggesting a FoxC2-Etv2-DNA
ternary complex (lanes 6–8). Relative levels of FoxC2 and Etv2 protein and binding activity are indicated at the top of the panel. In all samples, the total amount
of total protein was held constant by the addition of the appropriate amount of unprogrammed reticulocyte lysate.
(G) A 3 bpmutation (CATAACAGGAA to CATAtCtaGAA) of the FOX:ETSmotif (mutFEM) or mutation of the ETS-B site in the context ofMef2c F10, which contains
both neural crest and endothelial enhancers, results in loss of transgene expression in the endothelium but not the neural crest. The resultant transgenic embryos
show expression patterns similar to those in which the entire 44 bp element was deleted from F10 (Mef2c F10D44). Representative transgenic embryos from each
construct are shown.Cell 135, 1053–1064, December 12, 2008 ª2008 Elsevier Inc. 1057
The FOX:ETS Motif Is Present in Many
Endothelial-Specific Enhancers
The combined requirement for FoxC and Ets factors in vascular
development suggested that other endothelial-specific en-
hancers besidesMef2c F10Emight also contain similar FOX:ETS
motifs and be direct transcriptional targets of FoxC2 and Etv2.
An examination of previously identified endothelial-specific en-
hancer elements revealed the presence of FOX:ETS motifs,
including similar noncanonical Forkhead sites, in the FLK1,
TIE2, TAL1 (SCL), NOTCH4, and VE-CADHERIN (CDH5) en-
Figure 3. Misexpression of FoxC2 and Etv2 in Xenopus Embryos
Induces Ectopic Endothelial Gene Expression
Xenopus embryos were injected with mRNAs encoding FoxC2 and Etv2 or
EGFP control mRNA at the 4-cell stage and then collected at stage 36. After
collection, embryos were either assayed by in situ hybridization using flk1
probe, followed by sectioning (A and B), or RNA was extracted for qPCR anal-
ysis of flk1 (C) orPecam (D) transcripts. (A and B) flk1 expressionwas observed
in the cardinal veins (CVs) in control (A) and FoxC2 + Etv2-injected (B) em-
bryos. In addition, ectopic expression of flk1was readily observed in the endo-
derm of the caudal region of FoxC2 + Etv2-injected embryos (B) but not in
EGFP control injected embryos (A).
(C and D) Quantitative, real-time PCR shows that neither FoxC2 nor Etv2 sig-
nificantly activated flk1 orPecam expression on their own, but the combination
of the two factors strongly induced expression of both endothelial-specific
markers. Data are shown as the mean relative expression of flk1 or Pecam
transcripts for three independent sets of injections and analyses. Error bars
indicate the SEM.1058 Cell 135, 1053–1064, December 12, 2008 ª2008 Elsevier Inc.hancers (Figure 5A) (Dube et al., 1999; Gottgens et al., 2002;
Kappel et al., 1999; Prandini et al., 2005; Wu et al., 2005). Similar
to theMef2c FOX:ETSmotif, each of the elements was bound ro-
bustly and specifically by FoxC2 and Ets in EMSA, andmutations
within each of the FOX:ETSmotifs abolished binding (Figure 5C).
ChIP analyses demonstrated that the enhancer regions of each
of these additional genes were bound by FoxC2 in vivo
(Figure 5B).
Next, we tested whether the Flk1, Tie2, Tal1, NOTCH4, and
VE-CADHERIN enhancers were synergistically activated by the
combinatorial action of FoxC2 and Etv2 in transfection analyses
(Figure 6). In all cases, FoxC2 and Etv2 by themselves only
weakly activated the enhancers. However, in combination, the
two transcription factors caused synergistic activation of the en-
hancers (Figures 6A–6E, lanes 1–4). Furthermore, mutation of the
FOX:ETS motif in the VE-CADHERIN enhancer disrupted activa-
tion by FoxC2 and Etv2 in trans-activation assays (Figure 6E,
lanes 5–8) and completely abolished endothelial-specific ex-
pression of lacZ in transgenic embryos (Figures 6F and 6G).
The Presence of a FOX:ETS Motif Is Sufficient
to Identify Novel Endothelial-Specific Enhancers
The observation that multiple, well-established endothelial-spe-
cific enhancers contained functional FOX:ETS motifs suggested
that this element might be present in many enhancers of genes
expressed in the endothelium. To determine if the FOX:ETSmotif
was overrepresented within endothelial cell-expressed gene
loci, we performed a computational screen to search for the
presence of a FOX:ETS motif and a second ETS site within
60 bp (Figure 7). We included the requirement for a second
core ETS-binding site (GGAA/T) as part of our computational
screen since a second ETS site was found within 60 bp of the
FOX:ETS motif in all of the enhancers listed in Figure 5A.
Figure 7A shows a sequence logo representation of the position
weight matrix used as the FOX:ETS consensus motif. Our com-
putational screen identified the FOX:ETS motif within all six reg-
ulatory elements shown in Figure 5A, which served as an impor-
tant validation of the computational parameters of the screen.
We identified 445 deeply conserved FOX:ETS motifs with
a neighboring equally conserved second ETS site in the human
genome. When the search was conducted such that the
second ETS site only had to be conserved between mouse
and human, 1500 FOX:ETS motifs, associated with 1200 genes,
were identified.
We compared the distribution of positive hits from this screen
in three predetermined sets of genes: 69 known endothelial cell-
expressed genes, 305 housekeeping genes, and 75 skeletal
muscle-expressed genes (Table S1). We observed a highly sig-
nificant enrichment of the FOX:ETS motif and second ETS site
in the endothelial gene set compared to the housekeeping and
skeletal muscle gene sets (Figure 7B; p < 108). There was
also a slight enrichment for hematopoietic genes, which were
identified at 23% of the frequency of endothelial genes (150/445
endothelial versus 35/445 hematopoietic). Some association of
the FOX:ETS motif with hematopoietic genes was expected
given the numerous genes that are coexpressed in blood and en-
dothelial cells and the likely existence of a common progenitor
cell for the two lineages (Baron, 2003). Taken together, our
Figure 4. Combinatorial Regulation of Vascular Development in Zebrafish by FoxC and Ets Proteins
(A–D) The mouse Mef2c F10E enhancer directs expression of the GFP reporter gene in the vascular endothelium of transgenic zebrafish (A and B) in a nearly
identical pattern to the endothelial-specific Tg(flk1:GFP)s843 reporter (C and D).
(E–H) In situ hybridization shows that the zebrafish foxc genes foxc1a (E and F) and foxc1b (G and H) are expressed in the developing vasculature at 24 hpf.
(I–L) Knockdown of foxc1a and foxc1b bymorpholino injection alone (J and K) and in combination (L) resulted in loss of vascular structure, as detected by reduced
expression of Tg(flk1:GFP)s843 (green) and the pooling of blood, as indicated by Tg(gata1:DsRed)sd2 expression (red). The combined foxc1a/foxc1b knockdown (L)
resulted in a more severe perturbation of vascular development than either single knockdown. Note the normal expression of Tg(flk1:GFP)s843 and Tg(gata1:
DsRed)sd2 in the control morpholino-injected embryo (I).
(M–P) Injection of subphenotypic doses of foxc1a (N) and etsrp (O) morpholinos resulted in normal vascular development and normal expression of
Tg(flk1:GFP)s843 and Tg(gata1:DsRed)sd2 in patterns identical to control injected embryos (M). Coinjection of the lower doses of foxc1a and etsrp morpholinos
resulted in a nearly complete loss of vascular development (P). Asterisks mark the pooling of blood. Arrowheads point to the developing axial vessels, and arrows
indicate the developing intersomitic vessels.observations support the idea that the FOX:ETS motif is a com-
mon feature of many endothelial-specific genes and that its
presence might be used to identify endothelial-specific en-
hancers and genes computationally.
As an initial test to determine if the presence of the FOX:ETS
motif was sufficient to identify vascular enhancers, we investi-
gated the FOX:ETS regions identified in our computational
screen within 13 genes expressed in endothelial cells (Table
S2). EMSA analyses demonstrated that 10 of the 13 FOX:ETS
motifs were bound by FoxC2 and Etv2 proteins in vitro (data
not shown). Among the 10 regions validated by EMSA, we
tested eight for enhancer function in transgenic mouse em-
bryos. In each case, a region of approximately 1 kb encompass-
ing the FOX:ETS motif was tested in transient transgenic re-
porter assays for enhancer activity in mice at E9.5. Among the
eight fragments tested, five functioned as endothelial-specific
enhancers in transgenic embryos (Figure 7C). The five en-
hancers identified using this approach, from the human FLT4
(VEGFR3), PDGFRb, ECE1, NRP1, and FOXP1 genes, were all
novel and none demonstrated extensive sequence conservationbeyond the FOX:ETS motif and second ETS site, such that
depth of sequence conservation alone would not have predicted
these bona fide endothelial enhancers. Thus, these studies indi-
cate the importance of the FOX:ETS motif as a predictive tool for
the unbiased identification of endothelial enhancers based on its
presence.
DISCUSSION
Induction of Endothelial Gene Expression by the
Combinatorial Action of Forkhead and Ets Factors
It is well established that members of the Ets transcription factor
family are involved in the development of the endothelium, but
the mechanism by which they contribute to the specificity of en-
dothelial gene expression has been a key conundrum in vascular
biology since no Ets factor is unique to the vasculature (Hollen-
horst et al., 2004; Maroulakou and Bowe, 2000). In this paper,
we discovered that Ets factors function in combination with
FoxC proteins, which are also not restricted to the vasculature
(Carlsson and Mahlapuu, 2002; Dejana et al., 2007). It is likelyCell 135, 1053–1064, December 12, 2008 ª2008 Elsevier Inc. 1059
Figure 5. The FOX:ETS Motif Is Present in
Multiple Endothelial Enhancers
(A) Sequence and genomic location of FOX:ETS
motifs in MEF2C and five other known endothe-
lial-specific regulatory elements. The ETS sites
are highlighted in red, and the FOX-NC sites are
highlighted in blue. Chromosome locations refer
to the May 2004 assembly of the human genome.
(B) ChIP from primary mouse embryo fibroblasts
transfected with pCDNA3.1-FoxC2-FLAG (C2) or
parental pCDNA3.1 expression vector (ctrl) shows
that FoxC2 binds to the FOX:ETS motif in the
endogenous endothelial enhancers of the ortholo-
gous mouse genes. Human gene names are
shown. In each case, the FOX:ETS motif is per-
fectly conserved. In each case, the enhancer
regions were specifically amplified in pDNA3.1-
FoxC2-FLAG transfected cells (lane 5), similar to
the amplification in control samples that were di-
rectly amplified without prior immunoprecipitation
(input, lanes 1 and 3). No amplification was de-
tected in control transfected (lane 2) and nonspe-
cific IgG immunoprecipitated samples (lane 4).
Note that these reactions were performed in con-
junction with the ChIP for the myogenin promoter
region, shown in Figure 2D, which also serves as
a nonspecific control for these endogenous
genes.
(C) EMSA demonstrates that FoxC2 (lanes 2, 8, 14,
20, and 26) and Ets1 DBD (lanes 5, 11, 17, 23, and
29) bind directly to the FOX:ETS motifs present in
FLK1, TEK (Tie2), TAL1, NOTCH4, and CDH5
(VE-CADHERIN). In each case, an excess of unla-
beled FOX:ETS motif self-probe (wt) efficiently
competed for binding of FoxC2 and Ets1 DBD.
Small mutations within the FOX-NC site (mu) dis-
rupted competition by unlabeled probes even
when added in 503 excess (lanes 4, 10, 16, 22,
and 28).that several members of the Forkhead and Ets transcription fac-
tor families may be involved in vascular regulation via the FOX:
ETS motif. In addition to Etv2, other Ets factors activated en-
hancers containing the FOX:ETS motif and induced ectopic
vascular gene expression in Xenopus in concert with FoxC
(data not shown). Foxc1/Foxc2 compound null mice have severe
vascular defects (Seo et al., 2006), and we show here that com-
bined knockdown of the two foxc genes in zebrafish also se-
verely disrupts vascular development. However, some endothe-
lial specification clearly still occurs in both fish and mice lacking
FoxC function, supporting a possible role for other Forkhead
proteins. Consistent with this notion, the Mef2c FOX:ETS motif
was also bound by FoxO1 in the studies presented here, and
Foxo1 null mice die by E10.5 with incomplete vascular develop-
ment (Furuyama et al., 2004; Hosaka et al., 2004).
Tissue-Specific Enhancer Prediction Based on the
Presence of a Signature cis-Acting Element
The haploid human genome contains nearly 3 billion base pairs,
but only about 1.5% of this sequence is protein encoding. Much
of the non-protein-encoding sequence has been conserved for1060 Cell 135, 1053–1064, December 12, 2008 ª2008 Elsevier Inc.hundreds of millions of years and performs many functions,
including regulation of gene expression. However, the ability
to predict functional regulatory elements within vertebrate
genomes based solely on sequence information is poor. En-
hancer elements have been accurately predicted in mammalian
genomes only by screening for large numbers of different binding
motifs or by using extreme levels of conservation (Hallikas et al.,
2006; Pennacchio et al., 2006). Our recent use of deep phyloge-
netic conservation to identify enhancers successfully defined
numerous regulatory elements, but interestingly, these studies
did not identify a single enhancer directing expression to the vas-
culature, suggesting that using sequence conservation between
species alone was not an effective approach to identify endothe-
lial enhancers (Pennacchio et al., 2006).
The identification of a 44 bp enhancer fromMef2c that alone is
sufficient to direct endothelial-specific expression is unprece-
dented with regard to its small size and allowed us to identify
the FOX:ETS motif, a composite cis-acting element essential for
enhancer function in vivo. Interestingly, although the most highly
conserved 44 bp ofMef2c F10E (F10-44) was sufficient to direct
endothelial-specific expression throughout early embryogenesis,
Figure 6. FoxC2 and Etv2 Synergistically Activate Multiple Endothelial Enhancers
(A–E) FoxC2 and Etv2 synergistically trans-activate the Flk1 (A), Tie2 (B), Tal1 (C), NOTCH4 (D), and VE-CADHERIN/CDH5 (E) enhancers. Data are presented as
the mean fold activation for three to six independent sets of transfections and analyses. Error bars indicate the SEM. Note that in (E), a 4 bp mutation in the FOX:
ETS motif (mutFEM) completely abolished activation of the VE-CADHERIN promoter/enhancer by FoxC2 and Etv2.
(F and G) Mutation of the FOX:ETS motif within the 3.5 kb VE-CADHERIN promoter/enhancer completely disrupts VE-CADHERIN-lacZ transgene expression
at E9.5 (G) when compared to the strong, vascular-specific expression of the wild-type transgene (F). All five embryos transgenic for the wild-type 3.5 kb VE-
CADHERIN enhancer expressed lacZ robustly in the endothelium, while none of the three embryos transgenic for the mutated enhancer showed detectable
expression.the activity of this small enhancer was extinguished after E10.5.
By contrast, the larger 900 bp F10E construct remained active
exclusively in endothelial cells of both the blood and lymphatic
vasculature throughout embryogenesis and in adulthood (data
not shown). It is important to note that the 900 bp F10E construct
still required an intact FOX:ETSmotif for activity at later stages in
development. These data suggest that additional cis-acting
elements are involved in endothelial-specific maintenance of
the larger enhancer fragment and support a model in which the
FOX:ETS motif serves as an ancient, endothelial-specific initia-
tion element to which additional complexity has been added
throughout evolution. Consistent with this notion, there is exten-sive homology within Mef2c F10E beyond the FOX:ETS motif,
although the cross-species homology is not as deep as the
FOX:ETS motif (Figure S4). Furthermore, additional complexity
may have been added to the FOX:ETS motif in enhancers with
activity that restricts to distinct endothelial compartments, such
as arteries, veins, and lymphatics. Testing additional putative
enhancers in transgenic mice should allow for the identification
of other cis-motifs that are overrepresented in endothelial en-
hancers and are associated with the FOX:ETS motif. In addition,
these studies may establish a model for enhancer prediction
that may be applicable to any lineage or sublineage once there
is adequate understanding of required cis-elements.Cell 135, 1053–1064, December 12, 2008 ª2008 Elsevier Inc. 1061
Figure 7. Prediction of Endothelial-Specific Enhancers Based on the Presence of a FOX:ETS Motif
(A) Sequence logo representing the position weight matrix of the consensus FOX:ETS motif used in a genome-wide scan.
(B) The FOX:ETS motif is overrepresented in endothelial genes when compared to housekeeping and skeletal-muscle-expressed genes.
(C) Identification of five novel endothelial-specific enhancers from the whole-genome screen based on the presence of a FOX:ETSmotif. The upper row of photos
shows representative whole-mount X-gal-stained transient transgenic embryos at E9.5 from the ECE1, FLT4, PDGFRb, NRP1, and FOXP1 genes. Each directed
strong lacZ expression specifically to the endothelium, which can be clearly seen in transverse sections taken from each of the transient transgenic analyses at
E9.5 (lower row of photos). CV, cardinal vein; DA, dorsal aorta; hrt, heart; LV, left ventricle; NT, neural tube; RV, right ventricle; SV, sinus venosus.The Fox-Ets Interaction as a Target for Modulation
of Vascular Growth and Remodeling
Aberrant vessel growth is an important contributor to several
prevalent disease states (Carmeliet and Jain, 2000). Improper
overgrowth of blood vessels is an important cause of age-related
macular degeneration, and neovascularization of the retina is the
hallmark of proliferative diabetic retinopathy (Andreoli andMiller,
2007; Simo et al., 2006). Likewise, growth andmetastasis of solid
tumors requires an adequate blood supply, and angiogenic in-
duction of new blood vessel growth into tumors is an important
component of cancer pathology (Stacker et al., 2002). Current
strategies to inhibit angiogenesis are primarily based on blocking
vascular endothelial growth factor (VEGF) signaling (anti-VEGF
therapy), and the use of a monoclonal antibody against VEGF
has been shown to be clinically effective when used in combina-
tion with other chemotherapeutic agents (Goh et al., 2007). How-
ever, drug resistance of metastatic tumors is a concern, and the
identification of additional targets for blocking vessel growth re-
mains an important goal for cancer therapy (Goh et al., 2007).
The observation that the FOX:ETS motif is strongly associated
with numerous endothelial genes in the human genome sug-
gests that blocking activation via the FOX:ETS motif might suffi-
ciently inhibit the endothelial transcriptional program to serve as
a novel target for therapeutic intervention in cancer and other
diseases involving aberrant vessel growth.1062 Cell 135, 1053–1064, December 12, 2008 ª2008 Elsevier Inc.EXPERIMENTAL PROCEDURES
Plasmids, Cloning, and Mutagenesis
The 5550 bp F10 fragment fromMef2cwas generated by PCR and cloned into
the transgenic reporter plasmid HSP68-lacZ (De Val et al., 2004). F10-44 was
created by cloning complementary oligonucleotides, corresponding to the
44 bp deeply conserved F10 sequence, into HSP68-lacZ. The mouse flk1,
mouse Tie2, and humanNOTCH4 enhancers were generated by PCR from ge-
nomic DNA and cloned into p-TK-b-gal. The Tal1 (SCL +19) enhancer, which
has been described (Gottgens et al., 2002), was subcloned into p-TK-b-gal.
The 3564 bp and 377 bp VE-CADHERIN promoter/enhancer fragments were
generated by PCR fromhuman genomic DNA and cloned into the promoterless
lacZ reporter plasmidp-AUG-b-gal for thegenerationof transgenicmiceand for
use in transfection assays. The FLT4, FOXP1, NRP1, ECE1, PDGFRb, NR4A3,
EFNB1, and FGFR2 enhancers were amplified from human genomic DNA by
PCR and cloned into HSP68-lacZ.
For zebrafish transgenesis, the 885 bpMef2c F10E enhancer fragment was
cloned upstream of an HSP70-GFP cassette. For generating foxc1a and
foxc1b in situ probes, 800 bp at the 30 end of these genes including the
30 UTRwere PCR amplified. The Xenopus flk1 in situ probe has been described
previously (Cleaver et al., 1997). Expression plasmids were generated by clon-
ing cDNAs into plasmid pRK5.
Oligonucleotides and Morpholino Oligonucleotides
The sequences of oligonucleotide primers for cloning, mutagenesis, morpho-
lino knockdowns, qPCR detection of Xenopus laevis Pecam and flk1, and ChIP
detection are provided in Table S3. Oligonucleotide primer sequences used in
EMSA are provided in Table S4. The morpholino oligonucleotides for etsrp,
foxc1a, and foxc1b have been described previously (Pham et al., 2007; Top-
czewska et al., 2001).
Mice, Frogs, and Zebrafish
Transgenicmicewere generated by oocytemicroinjection, and genotype anal-
ysis and X-gal staining were performed as described previously (De Val et al.,
2004). Zebrafish whole-mount in situ hybridization was performed as previ-
ously described (Jin et al., 2005). To generateMef2c-GFP transgenic zebrafish,
embryoswere injectedwith 20–50 ng of construct at the one-cell stage and an-
alyzed at 24–48 hpf. Morpholino analyses were performed in Tg(flk1:GFP)s843;
Tg(gata1:DsRed)sd2 embryos (Jin et al., 2005; Traver et al., 2003). Embryos of
the frog Xenopus laevis were microinjected and incubated as described previ-
ously (Cleaver et al., 1997). RNA encoding EGFP was included in all injections
as a lineage tracer. Transcript levels for flk1 and Pecam were assayed by
qRT-PCR using normalized samples and SYBR-Green (Invitrogen). All experi-
ments using animals complied with federal and institutional guidelines.
Cell Culture, Transfections, and Chromatin Immunoprecipitation
For transient transfection assays, Cos1 cells were grown in DMEM supple-
mented with 10% FBS and seeded at 6 3 104 cells/2.5 cm plate. After 24 hr,
750 ng each of reporter and expression plasmids were transfected using
FuGENE6 (Roche) as recommended by the manufacturer. All transfections
lacking an expression plasmid contained an equal amount of the parental ex-
pression vector. Following transfection, cells were cultured for 48 hr, then har-
vested and assayed using the Luminescent b-galactosidase Detection kit II
(Clontech), as previously described (Rojas et al., 2008).
For ChIP, primary mouse embryo fibroblasts (MEFs) were transfected using
Lipofectamine LTX and 8 mg of either pcDNA3.1-FLAG-FoxC2 or empty
pCDNA3.1 vector in 10 cm dishes. Thirty-six hours after transfection, cells
were harvested as described previously (Rojas et al., 2008). ChIP was then
performed using the ChIP assay kit (Upstate/Millipore) according to the man-
ufacturer’s instructions, using anti-FLAG antibody (clone M2, Sigma) and pro-
tein A-agarose. Immunoprecipitated fragments and unprecipitated lysates
(input samples) were subjected to PCR using primers listed in Table S3.
Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assay (EMSAs) were performed as described
previously (De Val et al., 2004). All recombinant proteins were generated using
the TNT Quick Coupled Transcription/Translation System (Promega) accord-
ing to the manufacturer’s instructions. Full-length FoxC1, FoxC2, FoxA2,
FoxF1, FoxH1, Erg1, and Etv2 were expressed from either pCS2 or pcDNA3
expression plasmids using SP6 polymerase. FoxF1, FoxO1, Elf-1, and the
Ets1 DBD (De Val et al., 2004) were expressed from the pCITE2A in vitro
expression vectors, using T7 polymerase (Novagen).
Identification of Conserved Sequence Motifs
The sequences within and 10 kb around all human genes in the RefSeq data-
base (Pruitt et al., 2005) were scanned utilizing rVista (Loots et al., 2002). The
position weight matrix for the FOX:ETS motif, which was derived from the six
FOX:ETS sequences shown in Figure 5A plus 11 additional FOX:ETS motifs
identified experimentally as bound by FoxC2 and Etv2 in EMSA, and a second
consensus ETS site were used to scan mouse and human gene sequences in-
dependently. Hits in which the depth of conservation of the FOX:ETSmotif was
less than the surrounding 20 bp of sequencewere discounted, aswere those in
which the depth of conservation of the second ETS site was not equal to that of
the FOX:ETS motif.
SUPPLEMENTAL DATA
SupplementalData include fourfiguresand four tablesandcanbe foundwith this
article online at http://www.cell.com/supplemental/S0092-8674(08)01387-1.
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